Trial Comparing Intestinal Fluid Reinfusion Versus Water Infusion Through Ileal Stoma to Prevent Low Anterior Resection Syndrome After Rectal Cancer Surgery

What this Trial Is About

Researchers are investigating if antegrade intestinal fluid reinfusion can prevent low anterior resection syndrome LARS in patients who have a prophylactic ileal stoma after low anterior resection surgery for rectal cancer. This study compares intestinal fluid reinfusion to water infusion to see which method is more effective in preventing LARS. It is a randomized controlled trial conducted at a single center and sponsored by Pei-Rong Ding. Participants will begin treatment one month after their anterior rectal resection with ileostomy surgery. They will receive either reinfusion of their own intestinal fluid diluted with warm saline or potable water through the distal end of the ileal stoma every other day until the ileostomy reversal surgery. Both groups receive instructions on enema procedures from an enterostomal therapist. During the study, participants will keep a diary of their symptoms. Researchers will assess outcomes including LARS scores and quality of life at multiple timepoints up to 12 months after ileostomy reversal. Safety and symptom monitoring will continue throughout the study period. Participation will last from one month post-surgery through at least one year after ileostomy reversal.

Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial.